{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:57:51Z","timestamp":1793383071716,"version":"4.5.0"},"reference-count":158,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","aaojournal.org","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ophtha.2018.04.040","type":"journal-article","created":{"date-parts":[[2018,7,13]],"date-time":"2018-07-13T09:54:04Z","timestamp":1531475644000},"page":"1741-1756","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":243,"title":["Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension"],"prefix":"10.1016","volume":"125","author":[{"given":"Angelo P.","family":"Tanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2018.04.040_bib1","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: a review","volume":"311","author":"Weinreb","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ophtha.2018.04.040_bib2","series-title":"Principles and Practice of Ophthalmology","article-title":"Mechanisms and routes of aqueous humor drainage","author":"Johnson","year":"2000"},{"key":"10.1016\/j.ophtha.2018.04.040_bib3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.exer.2005.10.011","article-title":"What controls aqueous humour outflow resistance?","volume":"82","author":"Johnson","year":"2006","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2018.04.040_bib4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1001\/archopht.1951.01700020119001","article-title":"Clinical measurements of aqueous outflow","volume":"46","author":"Grant","year":"1951","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1055\/s-2008-1050606","article-title":"Zur Geschichte des Glaukoms","volume":"188","author":"Grewe","year":"1986","journal-title":"Klin Mbl Augenheik"},{"key":"10.1016\/j.ophtha.2018.04.040_bib6","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/0002-9394(76)90011-8","article-title":"Changes in the facility of aqueous outflow induced by lens depression and intraocular pressure in excised human eyes","volume":"82","author":"Van Buskirk","year":"1976","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib7","first-page":"625","article-title":"Anatomic correlates of changing aqueous outflow facility in excised human eyes","volume":"22","author":"Van Buskirk","year":"1982","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib8","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/0002-9394(73)90555-2","article-title":"Lens depression and aqueous outflow in enucleated primate eyes","volume":"72","author":"Van Buskirk","year":"1973","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0161-6420(82)34811-3","article-title":"Hazards of medical glaucoma therapy in the cataract patient","volume":"89","author":"Van Buskirk","year":"1982","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.04.040_bib10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0161-6420(82)34866-6","article-title":"Side effects and ways to avoid them","volume":"89","author":"Zimmerman","year":"1982","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.04.040_bib11","series-title":"Chandler and Grant\u2019s Glaucoma","first-page":"539","author":"Epstein","year":"1986"},{"key":"10.1016\/j.ophtha.2018.04.040_bib12","series-title":"Ophthalmology, Principles and Concepts","first-page":"529","author":"Newell","year":"1974"},{"key":"10.1016\/j.ophtha.2018.04.040_bib13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0161-6420(81)35042-8","article-title":"Toxicity of dipivalyl epinephrine","volume":"88","author":"Wandel","year":"1981","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.04.040_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00061198-199502000-00012","article-title":"The development of topical carbonic anhydrase inhibitors","volume":"4","author":"Maren","year":"1995","journal-title":"J\u00a0Glaucoma"},{"key":"10.1016\/j.ophtha.2018.04.040_bib15","first-page":"6","article-title":"Long-term glaucoma treatment with MK-507, dorzolamide, a topical carbonic anhydrase inhibitor","volume":"4","year":"1995","journal-title":"J\u00a0Glaucoma"},{"key":"10.1016\/j.ophtha.2018.04.040_bib16","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1001\/archopht.117.5.586","article-title":"Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents","volume":"117","author":"Maus","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib17","first-page":"1125","article-title":"Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits","volume":"16","author":"Camras","year":"1977","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib18","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1001\/archopht.1991.01080110100045","article-title":"PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers","volume":"109","author":"Alm","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib19","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/archopht.1987.01060080114039","article-title":"Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of uveoscleral outflow by prostaglandin F2 alpha","volume":"105","author":"Crawford","year":"1987","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib20","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0161-6420(96)30407-7","article-title":"Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups","volume":"103","author":"Camras","year":"1996","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.04.040_bib21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0014-4835(71)90149-7","article-title":"Uveoscleral drainage of aqueous humor in human eyes","volume":"12","author":"Bill","year":"1971","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2018.04.040_bib22","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.exer.2016.01.017","article-title":"Unconventional aqueous humor outflow: a review","volume":"158","author":"Johnson","year":"2017","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2018.04.040_bib23","first-page":"7623","article-title":"Circadian variation of aqueous humor dynamics in older healthy adults","volume":"54","author":"Nau","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/0014-4835(88)90043-7","article-title":"Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2a","volume":"47","author":"L\u00fctjen-Drecoll","year":"1988","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2018.04.040_bib25","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0002-9394(99)00076-8","article-title":"Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients","volume":"128","author":"Toris","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib26","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0039-6257(03)00003-1","article-title":"Targeting outflow facility in glaucoma management","volume":"48","author":"Brubaker","year":"2003","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib27","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1089\/jop.2017.0051","article-title":"Changing initial glaucoma medical therapy increases healthcare resource utilization","volume":"33","author":"Trese","year":"2017","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2018.04.040_bib28","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0161-6420(01)00873-9","article-title":"Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery","volume":"108","author":"Lichter","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.04.040_bib29","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib30","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/archophthalmol.2010.131","article-title":"Meta-analysis of the efficacy and safety of alpha2-adrenergic agonists, beta-adrenergic antagonists, and topical carbonic anhydrase inhibitors with prostaglandin analogs","volume":"128","author":"Tanna","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib31","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ophtha.2008.09.054","article-title":"Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy","volume":"116","author":"Liu","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.04.040_bib32","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.ophtha.2010.03.026","article-title":"Diurnal and nocturnal effects of brimonidine monotherapy on intraocular pressure","volume":"117","author":"Liu","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.04.040_bib33","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1007\/s12325-016-0389-3","article-title":"Additive intraocular pressure lowering effects of the rho kinase inhibitor, ripasudil in glaucoma patients not able to obtain adequate control after other maximal tolerated medical therapy","volume":"33","author":"Sato","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.ophtha.2018.04.040_bib34","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/IJG.0000000000000552","article-title":"Efficacy of the additional use of ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled under maximum medical therapy","volume":"26","author":"Inazaki","year":"2017","journal-title":"J\u00a0Glaucoma"},{"key":"10.1016\/j.ophtha.2018.04.040_bib35","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s00417-017-3727-5","article-title":"One-year efficacy of adjunctive use of ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy","volume":"255","author":"Inazaki","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib36","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ajo.2011.10.024","article-title":"Postoperative complications in the Tube Versus Trabeculectomy (TVT) study during five years of follow-up","volume":"153","author":"Gedde","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib37","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1167\/iovs.16-20710","article-title":"Mechanism of action of selective laser trabeculoplasty and predictors of response","volume":"58","author":"Gulati","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/08820538.2016.1228393","article-title":"Evolving surgical interventions in the treatment of glaucoma","volume":"32","author":"Bovee","year":"2017","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib39","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/jop.2013.0197","article-title":"Emerging trabecular outflow drugs","volume":"30","author":"Kopczynski","year":"2014","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2018.04.040_bib40","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archopht.116.5.633","article-title":"H-7 disrupts the actin cytoskeleton and increases outflow facility","volume":"116","author":"Tian","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib41","first-page":"931","article-title":"Latrunculin-A increases outflow facility in the monkey","volume":"40","author":"Peterson","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib42","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1006\/exer.1999.0797","article-title":"Effect of latrunculin-B on outflow facility in monkeys","volume":"70","author":"Peterson","year":"2000","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2018.04.040_bib43","first-page":"619","article-title":"Cytoskeletal involvement in the regulation of aqueous humor outflow","volume":"41","author":"Tian","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2013.05.002","article-title":"Rho-associated kinase inhibitors: a novel glaucoma therapy","volume":"37","author":"Inoue","year":"2013","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ophtha.2018.04.040_bib45","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3892\/ijo.2013.2100","article-title":"Rho\/Rho-associated kinase pathway in glaucoma (Review)","volume":"43","author":"Wang","year":"2013","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib46","first-page":"883","article-title":"An emerging treatment option for glaucoma: rho kinase inhibitors","volume":"8","author":"Wang","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib47","doi-asserted-by":"crossref","DOI":"10.4161\/sgtp.29770","article-title":"Rho GTPases as regulators of mitosis and cytokinesis in mammalian cells","volume":"5","author":"Chircop","year":"2014","journal-title":"Small GTPases"},{"key":"10.1016\/j.ophtha.2018.04.040_bib48","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrd1719","article-title":"Rho kinase, a promising drug target for neurological disorders","volume":"4","author":"Mueller","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ophtha.2018.04.040_bib49","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1124\/pr.115.010595","article-title":"Rho kinases in health and disease: from basic science to translational research","volume":"67","author":"Loirand","year":"2015","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.ophtha.2018.04.040_bib50","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/embor.2012.127","article-title":"Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy","volume":"13","author":"Rath","year":"2012","journal-title":"EMBO Rep"},{"key":"10.1016\/j.ophtha.2018.04.040_bib51","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ceb.2005.11.005","article-title":"Cofilin phosphatases and regulation of actin dynamics","volume":"18","author":"Huang","year":"2006","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib52","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jmb.2008.05.055","article-title":"Cofilin increases the bending flexibility of actin filaments: implications for severing and cell mechanics","volume":"381","author":"McCullough","year":"2008","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib53","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/cm.20472","article-title":"Rho-kinase\/ROCK: A key regulator of the cytoskeleton and cell polarity","volume":"67","author":"Amano","year":"2010","journal-title":"Cytoskeleton (Hoboken)"},{"key":"10.1016\/j.ophtha.2018.04.040_bib54","doi-asserted-by":"crossref","first-page":"C358","DOI":"10.1152\/ajpcell.90645.2007","article-title":"Myosin light chain kinase activation and calcium sensitization in smooth muscle in\u00a0vivo","volume":"295","author":"Mizuno","year":"2008","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib55","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2165\/00063030-200721030-00004","article-title":"Rho GTPase\/Rho kinase inhibition as a novel target for the treatment of glaucoma","volume":"21","author":"Rao","year":"2007","journal-title":"Biodrugs"},{"key":"10.1016\/j.ophtha.2018.04.040_bib56","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ajo.2013.05.016","article-title":"Phase 2 randomized clinical study of a rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension","volume":"156","author":"Tanihara","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib57","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00005-015-0382-6","article-title":"Novel insights into the roles of rho kinase in cancer","volume":"64","author":"Wei","year":"2016","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10.1016\/j.ophtha.2018.04.040_bib58","doi-asserted-by":"crossref","first-page":"e1225","DOI":"10.1038\/cddis.2014.191","article-title":"ROCK2 is a major regulator of axonal degeneration, neuronal death and axonal regeneration in the CNS","volume":"5","author":"Koch","year":"2014","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ophtha.2018.04.040_bib59","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.4103\/1673-5374.170325","article-title":"Gao H-y, Wang X-f. The role of the Rho\/ROCK signaling pathway in inhibiting axonal regeneration in the central nervous system","volume":"10","author":"Liu","year":"2015","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.ophtha.2018.04.040_bib60","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.tips.2010.12.006","article-title":"Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease","volume":"32","author":"Zhou","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib61","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1007\/s40265-014-0333-2","article-title":"Ripasudil: first global approval","volume":"74","author":"Garnock-Jones","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ophtha.2018.04.040_bib62","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1167\/iovs.13-13842","article-title":"The Novel Rho Kinase (ROCK) inhibitor K-115: a new candidate drug for neuroprotective treatment in glaucoma","volume":"55","author":"Yamamoto","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib63","doi-asserted-by":"crossref","first-page":"19640","DOI":"10.1038\/srep19640","article-title":"Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm\u2019s canal endothelial cells","volume":"6","author":"Kaneko","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ophtha.2018.04.040_bib64","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1016\/j.bmcl.2016.03.104","article-title":"Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma","volume":"26","author":"Sturdivant","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"issue":"5, Part A","key":"10.1016\/j.ophtha.2018.04.040_bib65","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.bbagen.2017.02.005","article-title":"Functions of Rho family of small GTPases and Rho-associated coiled-coil kinases in bone cells during differentiation and mineralization","volume":"1861","author":"Strzelecka-Kiliszek","year":"2017","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ophtha.2018.04.040_bib66","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1161\/hq1101.098486","article-title":"Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors","volume":"21","author":"Takemoto","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib67","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.atherosclerosis.2008.12.023","article-title":"Statins inhibit Rho kinase activity in patients with atherosclerosis","volume":"205","author":"Nohria","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ophtha.2018.04.040_bib68","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1167\/iovs.04-0776","article-title":"Effects of cholesterol-lowering statins on the aqueous humor outflow pathway","volume":"46","author":"Song","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib69","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.ophtha.2014.02.009","article-title":"Systemic medication and intraocular pressure in a British population: the EPIC-Norfolk Eye Study","volume":"121","author":"Khawaja","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.04.040_bib70","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0014-4835(77)80037-7","article-title":"Effect of cytochalasin B on conventional drainage of aqueous humor in the cynomolgus monkey: the ocular and cerebrospinal fluids","volume":"25","author":"Kaufman","year":"1977","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2018.04.040_bib71","first-page":"718","article-title":"Cytochalasin B-induced structural changes in the anterior ocular segment of the cynomolgus monkey","volume":"17","author":"Svedbergh","year":"1978","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib72","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1755-3768.1972.tb05954.x","article-title":"Scanning electron microscopic studies of the trabecular meshwork and the canal of Schlemm\u2013an attempt to localize the main resistance to outflow of aqueous humor in man","volume":"50","author":"Bill","year":"1972","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"10.1016\/j.ophtha.2018.04.040_bib73","first-page":"1670","article-title":"Modulation of outflow resistance by the pores of the inner wall endothelium","volume":"33","author":"Johnson","year":"1992","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib74","doi-asserted-by":"crossref","first-page":"13876","DOI":"10.1073\/pnas.1410602111","article-title":"Altered mechanobiology of Schlemm\u2019s canal endothelial cells in glaucoma","volume":"111","author":"Overby","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2018.04.040_bib75","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1167\/iovs.05-0327","article-title":"Effects of latrunculin-B on outflow facility and trabecular meshwork structure in human eyes","volume":"47","author":"Ethier","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib76","series-title":"Pathogenesis and Risk Factors of Glaucoma","article-title":"The actin cytoskeleton and aqueous outflow","author":"Tian","year":"1999"},{"key":"10.1016\/j.ophtha.2018.04.040_bib77","first-page":"239","article-title":"H-7 increases trabecular facility and facility after ciliary muscle disinsertion in monkeys","volume":"40","author":"Tian","year":"1999","journal-title":"Invest Opthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib78","first-page":"955","article-title":"H-7 effects on the structure and fluid conductance of monkey trabecular meshwork","volume":"118","author":"Sabanay","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib79","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.exer.2008.11.033","article-title":"The changing paradigm of outflow resistance generation: towards synergistics models of the JCT and inner wall endothelium","volume":"88","author":"Overby","year":"2009","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2018.04.040_bib80","first-page":"1029","article-title":"Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632","volume":"42","author":"Rao","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib81","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/archopht.119.8.1171","article-title":"Effects of protein kinase inhibitor, ha1077, on intraocular pressure and outflow facility in rabbit eyes","volume":"119","author":"Honjo","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib82","first-page":"137","article-title":"Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility","volume":"42","author":"Honjo","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib83","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.exer.2004.08.029","article-title":"Regulation of myosin light chain phosphorylation in the trabecular meshwork: role in aqueous humour outflow facility","volume":"80","author":"Rao","year":"2005","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2018.04.040_bib84","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1080\/02713680902783763","article-title":"The effect of the H-1152P, a potent Rho-associated coiled coil-formed protein kinase inhibitor, in rabbit normal and ocular hypertensive eyes","volume":"34","author":"Nishio","year":"2009","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ophtha.2018.04.040_bib85","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1167\/iovs.05-1617","article-title":"Effects of topical administration of Y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys","volume":"48","author":"Tokushige","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib86","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1089\/jop.2017.0023","article-title":"Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma","volume":"34","author":"Lin","year":"2018","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2018.04.040_bib87","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1167\/iovs.13-13157","article-title":"AMA0076, a novel, locally acting rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia","volume":"55","author":"Van de Velde","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib88","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/IJG.0b013e3182952213","article-title":"Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes","volume":"24","author":"Wang","year":"2015","journal-title":"J\u00a0Glaucoma"},{"key":"10.1016\/j.ophtha.2018.04.040_bib89","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3109\/02713683.2013.874444","article-title":"Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits","volume":"39","author":"Isobe","year":"2014","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ophtha.2018.04.040_bib90","first-page":"288","article-title":"Expression of dominant negative Rho-binding domain of Rho-kinase in organ cultured human eye anterior segments increases aqueous humor outflow","volume":"11","author":"Rao","year":"2005","journal-title":"Mol Vis"},{"key":"10.1016\/j.ophtha.2018.04.040_bib91","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1006\/exer.2002.2009","article-title":"A\u00a0myosin light chain kinase inhibitor, ML-9, lowers the intraocular pressure in rabbit eyes","volume":"75","author":"Honjo","year":"2002","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2018.04.040_bib92","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1098\/rsif.2011.0733","article-title":"Mechanical responsiveness of the endothelial cell of Schlemm\u2019s canal: scope, variability and its potential role in controlling aqueous humour outflow","volume":"9","author":"Zhou","year":"2012","journal-title":"J\u00a0R Soc Interface"},{"key":"10.1016\/j.ophtha.2018.04.040_bib93","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.preteyeres.2014.08.002","article-title":"Biomechanics of Schlemm\u2019s canal endothelium and intraocular pressure reduction","volume":"44","author":"Stamer","year":"2014","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ophtha.2018.04.040_bib94","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.exer.2007.10.018","article-title":"The mechanism of increasing outflow facility by rho-kinase inhibition with Y-27632 in bovine eyes","volume":"86","author":"Lu","year":"2008","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2018.04.040_bib95","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1089\/jop.2008.0029","article-title":"H-1152 effects on intraocular pressure and trabecular meshwork morphology of rat eyes","volume":"24","author":"Yu","year":"2008","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2018.04.040_bib96","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.1167\/iovs.16-20189","article-title":"Netarsudil increases outflow facility in human eyes through multiple mechanisms","volume":"57","author":"Ren","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib97","first-page":"4240","article-title":"Mediation of calcium-independent contraction in trabecular meshwork through protein kinase C and rho-A","volume":"41","author":"Thieme","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib98","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0014-4835(91)90141-Z","article-title":"Differential smooth muscle-like contractile properties of trabecular meshwork and ciliary muscle","volume":"53","author":"Lepple-Wienhues","year":"1991","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2018.04.040_bib99","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1167\/iovs.13-13091","article-title":"Circumferential tensile stiffness of glaucomatous trabecular meshwork","volume":"55","author":"Camras","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib100","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/archophthalmol.2007.76","article-title":"Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers","volume":"126","author":"Tanihara","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib101","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1111\/aos.12641","article-title":"Efficacy and safety of SNJ-1656 in primary open-angle glaucoma or ocular hypertension","volume":"93","author":"Inoue","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib102","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajo.2011.04.012","article-title":"Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension","volume":"152","author":"Williams","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib103","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/bjophthalmol-2012-302466","article-title":"Ocular hypotensive efficacy, safety and systemic absorption of AR-12286 ophthalmic solution in normal volunteers","volume":"97","author":"Kopczynski","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib104","doi-asserted-by":"crossref","first-page":"e807","DOI":"10.1097\/IJG.0000000000000508","article-title":"Efficacy of topically administered rho-kinase inhibitor AR-12286 in patients with exfoliation syndrome and ocular hypertension or glaucoma","volume":"25","author":"Skaat","year":"2016","journal-title":"J\u00a0Glaucoma"},{"key":"10.1016\/j.ophtha.2018.04.040_bib105","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1001\/jamaophthalmol.2013.323","article-title":"Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115","volume":"131","author":"Tanihara","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib106","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ajo.2013.05.016","article-title":"Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension","volume":"156","author":"Tanihara","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib107","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/aos.12599","article-title":"Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study","volume":"93","author":"Tanihara","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib108","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/jamaophthalmol.2015.0525","article-title":"Additive intraocular pressure-lowering effects of the rho kinase inhibitor ripasudil (K-115) Combined with timolol or latanoprost: a report of 2 randomized clinical trials","volume":"133","author":"Tanihara","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib109","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1111\/aos.12829","article-title":"One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension","volume":"94","author":"Tanihara","year":"2016","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib110","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ophtha.2014.08.022","article-title":"Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure","volume":"122","author":"Bacharach","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.04.040_bib111","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.ajo.2015.01.026","article-title":"Ocular hypotensive safety and systemic absorption of AR-13324 ophthalmic solution in normal volunteers","volume":"159","author":"Levy","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib112","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/bjophthalmol-2015-306778","article-title":"Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension","volume":"100","author":"Lewis","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib113","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","article-title":"Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure","volume":"186","author":"Serle","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib114","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/jop.2008.0142","article-title":"Decreased intraocular pressure in mice following either pharmacological or genetic inhibition of ROCK","volume":"25","author":"Whitlock","year":"2009","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2018.04.040_bib115","first-page":"4058","article-title":"Discovery and in\u00a0vitro SAR of AR-12286, a potent kinase inhibitor for the treatment of glaucoma","volume":"50","author":"deLong","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib116","unstructured":"Kopczynski C. Chief Scientific Officer, Aerie Pharmaceuticals, Inc. In: Tanna AP, ed. December 10, 2017 (personal communication)."},{"key":"10.1016\/j.ophtha.2018.04.040_bib117","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1080\/02713683.2016.1250276","article-title":"Time course of conjunctival hyperemia induced by a Rho-kinase inhibitor anti-glaucoma eye drop: ripasudil 0.4","volume":"42","author":"Terao","year":"2017","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ophtha.2018.04.040_bib118","first-page":"93","article-title":"Efficacy and safety of adding ripasudil to existing treatment regimens for reducing intraocular pressure","volume":"38","author":"Inoue","year":"2018","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib119","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1089\/jop.2016.0085","article-title":"A\u00a0rho-associated kinase inhibitor protects permeability in a cell culture model of ocular disease, and reduces aqueous flare in anterior uveitis","volume":"33","author":"Yamada","year":"2017","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2018.04.040_bib120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185305","article-title":"Comparison of intraocular pressure-lowering effects of ripasudil hydrochloride hydrate for inflammatory and corticosteroid-induced ocular hypertension","volume":"12","author":"Yasuda","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ophtha.2018.04.040_bib121","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejphar.2016.04.002","article-title":"Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes","volume":"787","author":"Li","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib122","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/jop.2014.0146","article-title":"Effect of AR-13324 on episcleral venous pressure in Dutch belted rabbits","volume":"31","author":"Kiel","year":"2015","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2018.04.040_bib123","first-page":"2112","article-title":"The effects of netarsudil ophthalmic solution on aqueous humor dynamics in humans","volume":"58","author":"Sit","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib124","unstructured":"Aerie Pharmaceuticals I. Aerie Pharmaceuticals, Inc. Presentation Regarding Rhopressa to Dermatologic and Ophthalmic Drugs Advisory Committee of the United States Food and Drug Administration. In: Administration US Food and Drug Administration, ed. 2017."},{"key":"10.1016\/j.ophtha.2018.04.040_bib125","unstructured":"Aerie Pharmaceuticals I. Aerie Pharmaceuticals Roclatan\u2122 Mercury Phase 3 Topline Efficacy Results Conference Call.\u00a02017; http:\/\/investors.aeriepharma.com\/static-files\/fb9a0c3f-7255-4b50-97b2-450a2ba5d139."},{"key":"10.1016\/j.ophtha.2018.04.040_bib126","doi-asserted-by":"crossref","first-page":"e676","DOI":"10.1097\/MJT.0000000000000362","article-title":"The ocular hypotensive efficacy of topical fasudil, a rho-associated protein kinase inhibitor, in patients with end-stage glaucoma","volume":"24","author":"Pakravan","year":"2017","journal-title":"Am J Ther"},{"issue":"12 Suppl","key":"10.1016\/j.ophtha.2018.04.040_bib127","first-page":"10","article-title":"A\u00a0randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide","volume":"106","author":"Boyle","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.04.040_bib128","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/archopht.124.9.1230","article-title":"Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial","volume":"124","author":"Sherwood","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib129","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/jop.2005.21.337","article-title":"Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension","volume":"21","author":"Craven","year":"2005","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"issue":"1-2","key":"10.1016\/j.ophtha.2018.04.040_bib130","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1089\/jop.2017.0023","article-title":"Discovery and preclinical development of Netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma","volume":"34","author":"Lin","year":"2018","journal-title":"J Ocular Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2018.04.040_bib131","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3389\/fnins.2015.00198","article-title":"Chatting with the neighbors: crosstalk between Rho-kinase (ROCK) and other signaling pathways for treatment of neurological disorders","volume":"9","author":"Hensel","year":"2015","journal-title":"Front Neurosci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib132","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.survophthal.2015.10.004","article-title":"Autoregulation and neurovascular coupling in the optic nerve head","volume":"61","author":"Prada","year":"2016","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib133","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1167\/iovs.10-6710","article-title":"Systemic vascular dysregulation and retrobulbar hemodynamics in normal-tension glaucoma","volume":"52","author":"Galassi","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib134","doi-asserted-by":"crossref","first-page":"a001818","DOI":"10.1101\/cshperspect.a001818","article-title":"Rho and Ras GTPases in axon growth, guidance, and branching","volume":"2","author":"Hall","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib135","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pneurobio.2015.06.002","article-title":"Towards axonal regeneration and neuroprotection in glaucoma: Rho kinase inhibitors as promising therapeutics","volume":"131","author":"Van de Velde","year":"2015","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib136","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0896-6273(02)01018-8","article-title":"Nogo on the go","volume":"36","author":"McKerracher","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.ophtha.2018.04.040_bib137","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1523\/JNEUROSCI.22-15-06570.2002","article-title":"Rho signaling pathway targeted to promote spinal cord repair","volume":"22","author":"Dergham","year":"2002","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib138","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1167\/tvst.6.3.22","article-title":"Fasudil, a clinically used ROCK inhibitor, stabilizes rod photoreceptor synapses after retinal detachment","volume":"6","author":"Townes-Anderson","year":"2017","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib139","doi-asserted-by":"crossref","first-page":"6885","DOI":"10.1007\/s12035-016-0187-6","article-title":"RhoA\/Rho kinase mediates neuronal death through regulating cPLA2 activation","volume":"54","author":"Wu","year":"2017","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib140","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/j.1471-4159.2004.02980.x","article-title":"Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurons","volume":"92","author":"Bosel","year":"2005","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.ophtha.2018.04.040_bib141","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.expneurol.2007.02.002","article-title":"A\u00a0novel ROCK inhibitor, Y-39983, promotes regeneration of crushed axons of retinal ganglion cells into the optic nerve of adult cats","volume":"205","author":"Sagawa","year":"2007","journal-title":"Exp Neurol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib142","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.exer.2016.07.006","article-title":"Topical administration of a Rock\/Net inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury","volume":"158","author":"Shaw","year":"2017","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2018.04.040_bib143","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/IJG.0b013e318241b83c","article-title":"Elevated levels of RhoA in the optic nerve head of human eyes with glaucoma","volume":"21","author":"Goldhagen","year":"2012","journal-title":"J\u00a0Glaucoma"},{"key":"10.1016\/j.ophtha.2018.04.040_bib144","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1111\/aos.12298","article-title":"Ocular perfusion pressure in glaucoma","volume":"92","author":"Costa","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib145","first-page":"849","article-title":"Dysfunctional regulation of ocular blood flow: a risk factor for glaucoma?","volume":"2","author":"Moore","year":"2008","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib146","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3109\/02713683.2011.599106","article-title":"Effects of Y-39983, a selective Rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats","volume":"36","author":"Tokushige","year":"2011","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ophtha.2018.04.040_bib147","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1167\/iovs.10-5265","article-title":"Effects of fasudil, a Rho-associated protein kinase inhibitor, on optic nerve head blood flow in rabbits","volume":"52","author":"Sugiyama","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib148","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10384-017-0524-y","article-title":"Effects of ripasudil hydrochloride hydrate (K-115), a Rho-kinase inhibitor, on ocular blood flow and ciliary artery smooth muscle contraction in rabbits","volume":"61","author":"Ohta","year":"2017","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib149","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10384-011-0048-9","article-title":"Effects of Rho-associated protein kinase inhibitors Y-27632 and Y-39983 on isolated rabbit ciliary arteries","volume":"55","author":"Watabe","year":"2011","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib150","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1167\/iovs.09-4391","article-title":"Divergent roles of nitric oxide and rho kinase in vasomotor regulation of human retinal arterioles","volume":"51","author":"Hein","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib151","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.ophtha.2017.11.029","article-title":"Glaucomatous optic neuropathy associated with nocturnal dip in blood pressure: findings from the Maracaibo Aging Study","volume":"6","author":"Melgarejo","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.04.040_bib152","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1167\/iovs.05-1053","article-title":"Effect of nocturnal blood pressure reduction on circadian fluctuation of mean ocular perfusion pressure: a risk factor for normal tension glaucoma","volume":"47","author":"Choi","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib153","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0039-6257(87)90091-9","article-title":"Wound healing in glaucoma filtering surgery","volume":"32","author":"Skuta","year":"1987","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.04.040_bib154","first-page":"1975","article-title":"Transforming growth factor-beta1, -beta2, and -beta3 in\u00a0vivo: effects on normal and mitomycin C-modulated conjunctival scarring","volume":"40","author":"Cordeiro","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib155","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1167\/iovs.06-0118","article-title":"Contractility as a prerequisite for TGF-beta-induced myofibroblast transdifferentiation in human tenon fibroblasts","volume":"47","author":"Meyer-ter-Vehn","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib156","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.exer.2016.07.001","article-title":"The effects of ripasudil (K-115), a Rho kinase inhibitor, on activation of human conjunctival fibroblasts","volume":"149","author":"Futakuchi","year":"2016","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2018.04.040_bib157","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1167\/iovs.07-0878","article-title":"Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery","volume":"48","author":"Honjo","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.04.040_bib158","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/bs.pbr.2015.04.014","article-title":"Rho kinase inhibitor AMA0526 improves surgical outcome in a rabbit model of glaucoma filtration surgery","volume":"220","author":"Van de Velde","year":"2015","journal-title":"Prog Brain Res"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642018304202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642018304202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T17:08:58Z","timestamp":1604596138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642018304202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":158,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0161642018304202"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2018.04.040","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2018.04.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}